Tripuraneni Radhika 4
4 · Viridian Therapeutics, Inc.\DE · Filed Mar 12, 2025
Insider Transaction Report
Form 4
Tripuraneni Radhika
Chief Medical Officer
Transactions
- Award
Stock Option (Right to Buy)
2025-03-10+310,700→ 310,700 totalExercise: $15.58Exp: 2035-03-10→ Common Stock (310,700 underlying)
Footnotes (1)
- [F1]The option vests as to 25% on March 10, 2026 and then in equal monthly installments over the following 36 months, subject to the Reporting Person's continued service to Issuer through each vesting date.